Literature DB >> 24214413

Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.

May Darwish-Yassine1, Manijeh Berenji, Diane Wing, Glenn Copeland, Raymond Y Demers, Carol Garlinghouse, Angela Fagerlin, Gail E Newth, Laurel Northouse, Margaret Holmes-Rovner, David Rovner, Jerry Sims, John T Wei.   

Abstract

CONTEXT: Advances in screening and treatment of prostate cancer have dramatically increased the number of survivors in the US population. Yet the effect of screening is controversial, and in some instances may not be beneficial. Previous studies have typically only reported outcomes of treatment and symptoms within a short time frame following treatment. The persistence of such symptoms over time necessitates an improvement of survivor care so that the medical and support needs of these patients are met.
OBJECTIVE: This study aims to perform a patient-centered survey of prostate cancer survivors in the Michigan Cancer Registry to identify treatment side effect rates, evaluate survivors' access to preventive care services post-prostate cancer treatment, and assess the informational needs of these survivors regarding their prostate cancer. DESIGN, SETTING, AND PATIENTS: Linking case files of the Michigan Cancer Registry with records from the National Death Index, we identified prostate cancer patients diagnosed between 1985 and 2004 and alive on 31 December 2005. Participants were selected using a stratified cross-sectional sampling strategy to ensure adequate inclusion of survivors based upon race and ethnicity, urban versus rural location, and number of years since diagnosis of prostate cancer. A total of 2,499 surveys were completed and returned. MAIN OUTCOME MEASURES: (1) Physical symptoms--assessing bowel, sexual, urinary, and vitality symptoms by treatment modality. (2) Access to care--identifying whether diagnostic tests for prostate cancer (prostate-specific antigen (PSA) and digital rectal examination) were performed. Determining whether the survivors had knowledge of the "watchful waiting" paradigm for prostate cancer surveillance. (3) Informational needs--assessing whether the informational needs of patients were addressed by providers. Evaluating the significant predictors associated with seeking information about prostate cancer from any other source. Identifying what factors influenced a person to actively seek out information and what factors guide which primary information source a survivor would use.
RESULTS: Median duration between prostate cancer diagnosis and survey response was 9 years. Of the study population, 80 % was diagnosed at an early stage. Survivors had reported significant problems in the 4 weeks prior to survey. Of the survivors, 88.1 % reported having a PSA test since diagnosis of prostate cancer, with 93 % of them having it done at least once per year. Of the survivors, 82.6 % reported that a healthcare provider gave them information on prostate cancer. Of this 82.6 %, 86.4 % had this information provided by a urologist, 45.4 % by a primary care physician, and 29.2 % by an oncologist. The primary source of information for these survivors was "healthcare provider" (59.2 %).
CONCLUSION: Persistent symptoms subsequent to prostate cancer treatment suggest a gap in symptom management. Future research should support long-term studies of active surveillance versus active treatment outcomes to understand the feasibility of minimizing the burden of long-term physical symptoms arising from prostate cancer treatment. Clinicians must assess post-treatment distress long after treatment has ended to identify when supportive care is needed. More informational resources should be allocated to prostate cancer survivors to ensure that they are well-educated about their prognosis. IMPLICATIONS FOR CANCER SURVIVORS: This study is needed to ensure that the post-treatment symptoms of prostate cancer survivors are properly addressed and managed by healthcare providers over the long term.

Entities:  

Mesh:

Year:  2013        PMID: 24214413     DOI: 10.1007/s11764-013-0312-8

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  32 in total

1.  Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.

Authors:  Celestia Higano; Andrew Shields; Nathanael Wood; Judy Brown; Cathy Tangen
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

2.  The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors.

Authors:  Tenbroeck Smith; Kevin D Stein; C Christina Mehta; Chiewkwei Kaw; James L Kepner; Trent Buskirk; Jeremy Stafford; Frank Baker
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

3.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

4.  Endogenous sex hormones and metabolic syndrome in aging men.

Authors:  Majon Muller; Diederick E Grobbee; Isolde den Tonkelaar; Steven W J Lamberts; Yvonne T van der Schouw
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

5.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Authors:  J T Wei; R L Dunn; M S Litwin; H M Sandler; M G Sanda
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

6.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Authors:  Milena Braga-Basaria; Adrian S Dobs; Denis C Muller; Michael A Carducci; Majnu John; Josephine Egan; Shehzad Basaria
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

7.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

8.  Primary care perspectives on prostate cancer survivorship: implications for improving quality of care.

Authors:  Ted A Skolarus; Margaret Holmes-Rovner; Laurel L Northouse; Angela Fagerlin; Carol Garlinghouse; Raymond Y Demers; David R Rovner; May Darwish-Yassine; John T Wei
Journal:  Urol Oncol       Date:  2011-07-20       Impact factor: 3.498

9.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

Authors:  H W Daniell; S R Dunn; D W Ferguson; G Lomas; Z Niazi; P T Stratte
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

10.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Authors:  Frances Dockery; Christopher J Bulpitt; Sanjiv Agarwal; Mandy Donaldson; Chakravarthi Rajkumar
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

View more
  19 in total

1.  [Internet use after prostate cancer : Search for information and trust in disease-related information in long-term survivors].

Authors:  A J Linden; A Dinkel; S Schiele; V H Meissner; J E Gschwend; K Herkommer
Journal:  Urologe A       Date:  2019-09       Impact factor: 0.639

2.  Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.

Authors:  Ted A Skolarus; Tabitha Metreger; Daniela Wittmann; Soohyun Hwang; Hyungjin Myra Kim; Robert L Grubb; Jeffrey R Gingrich; Hui Zhu; John D Piette; Sarah T Hawley
Journal:  J Clin Oncol       Date:  2019-03-29       Impact factor: 44.544

3.  Adult Cancer Survivors' Engagement and Interest in Patient-Centered Research.

Authors:  Margaret M Lubas; Yan Lu; Aaron W Gehr; Bassam Ghabach; Bhavna Tanna; Kalyani Narra; Tara M Brinkman; Rohit P Ojha
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-18       Impact factor: 4.254

4.  Prostate cancer-related anxiety in long-term survivors after radical prostatectomy.

Authors:  Valentin H Meissner; Kathleen Herkommer; Birgitt Marten-Mittag; Jürgen E Gschwend; Andreas Dinkel
Journal:  J Cancer Surviv       Date:  2017-05-21       Impact factor: 4.442

5.  Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form.

Authors:  Ted A Skolarus; Rodney L Dunn; Martin G Sanda; Peter Chang; Thomas K Greenfield; Mark S Litwin; John T Wei
Journal:  Urology       Date:  2015-01       Impact factor: 2.649

6.  Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care.

Authors:  Jennifer K Bernat; Daniela A Wittman; Sarah T Hawley; Daniel A Hamstra; Alexander M Helfand; David A Haggstrom; May Darwish-Yassine; Ted A Skolarus
Journal:  BJU Int       Date:  2015-10-26       Impact factor: 5.588

7.  Curcumin for the Treatment of Prostate Diseases: A Systematic Review of Controlled Clinical Trials.

Authors:  Mohammad Bagherniya; Gholamreza Askari; Babak Alikiaii; Saeed Abbasi; Davood Soleimani; Thozhukat Sathyapalan; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Health information needs and preferences in relation to survivorship care plans of long-term cancer survivors in the American Cancer Society's Study of Cancer Survivors-I.

Authors:  Mary Playdon; Leah M Ferrucci; Ruth McCorkle; Kevin D Stein; Rachel Cannady; Tara Sanft; Brenda Cartmel
Journal:  J Cancer Surviv       Date:  2016-01-07       Impact factor: 4.442

9.  Men's sexual help-seeking and care needs after radical prostatectomy or other non-hormonal, active prostate cancer treatments.

Authors:  Melissa K Hyde; Melissa Opozda; Kirstyn Laurie; Andrew D Vincent; John L Oliffe; Christian J Nelson; Jeff Dunn; Eric Chung; Michael Gillman; Rustom P Manecksha; Gary Wittert; Suzanne K Chambers
Journal:  Support Care Cancer       Date:  2020-09-26       Impact factor: 3.603

10.  Negative information-seeking experiences of long-term prostate cancer survivors.

Authors:  Jennifer K Bernat; Ted A Skolarus; Sarah T Hawley; David A Haggstrom; May Darwish-Yassine; Daniela A Wittmann
Journal:  J Cancer Surviv       Date:  2016-05-26       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.